Literature DB >> 1376263

T cell responses to human recombinant acetylcholine receptor-alpha subunit in myasthenia gravis and controls.

J B Sun1, G Harcourt, Z Y Wang, S Hawke, T Olsson, S Fredrikson, H Link.   

Abstract

Antibodies against the nicotinic acetylcholine receptor (AChR) of the neuromuscular junction are detectable in most patients with myasthenia gravis (MG) and assumed to participate in the destruction of the AChR, thereby, causing the characteristics signs and symptoms of the disease. The extent and importance of T cell responses to AChR and its subunits in MG are still unsettled. We have now examined T cell reactivities using human recombinant AChR-alpha subunit as antigen. Upon recognition of appropriate antigen in an MHC-class II-restricted fashion, memory T cells secrete interferon-gamma (IFN-gamma). Adopting this principle in an immunospot assay we found that 73% of MG patients had recombinant human AChR-alpha subunit-reactive T cells at a median value of 1 per 56,000 blood mononuclear cells, while only 27% of the MG patients responded to the alpha subunit in a conventional lymphocyte proliferation assay. This compares with even lower numbers of AChR-reactive T cells and 14% positivity in the proliferation assay among control subjects. The T cell responses to the control antigens purified protein derivative and myelin basic protein did not differ between MG and controls, underlining the specificity of an augmented T cell reactivity to AChR-alpha subunit in MG. Alpha Subunit-specific T cell lines and clones propagated from patients with MG and healthy controls yielded a high proportion of alpha subunit-reactive T cells in the IFN-gamma immunospot assay. Their appearance was inhibited by the addition of monoclonal anti-MHC class II antibodies, demonstrating that an MHC-restricted T cell response was measured. Our data underline that the AChR-alpha subunit is a major T cell autoantigen in MG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376263     DOI: 10.1002/eji.1830220631

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 2.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

3.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

4.  Differential expression of human nicotinic acetylcholine receptor alpha subunit variants in muscle and non-muscle tissues.

Authors:  S Talib; T B Okarma; J S Lebkowski
Journal:  Nucleic Acids Res       Date:  1993-01-25       Impact factor: 16.971

5.  Autoantigen-specific T cell proliferation induced by the ribosomal P2 protein in patients with systemic lupus erythematosus.

Authors:  M K Crow; G DelGiudice-Asch; J B Zehetbauer; J L Lawson; N Brot; H Weissbach; K B Elkon
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

6.  Analysis of T cell responses to the autoantigen in Goodpasture's disease.

Authors:  C J Derry; C N Ross; G Lombardi; P D Mason; A J Rees; R I Lechler; C D Pusey
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

Review 7.  Autoimmune Thyroiditis and Myasthenia Gravis.

Authors:  Angela Lopomo; Sonia Berrih-Aknin
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-13       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.